Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Rhythm Pharmaceuticals (RYTM) has reported Capital Leases for 4 consecutive years, with $1.8 million the latest figure, recorded in Q1 2022.

• In Q1 2022, Capital Leases fell 25.98% year-over-year to $1.8 million; the TTM figure through Mar 2022 stood at $1.8 million (down 25.98% YoY), while the FY2021 annual figure was $1.9 million, down 23.76% from the prior year.
• Capital Leases eased to $1.8 million in Q1 2022 per RYTM's latest filing, from $1.9 million in the prior quarter.
• Across five years, Capital Leases topped out at $3.4 million in Q1 2019 and bottomed at $1.8 million in Q1 2022.
• Historically, Capital Leases has averaged $2.6 million across 4 years, with a median of $2.6 million in 2020.
• Annual changes were most pronounced in 2020 — Capital Leases decreased 15.1% — and 2022, when it fell 25.98%.
• Rhythm Pharmaceuticals' Capital Leases stood at $3.1 million in 2019, then retreated by 17.34% to $2.6 million in 2020, then slipped by 23.76% to $1.9 million in 2021, then decreased by 8.43% to $1.8 million in 2022.
• Business Quant data shows RYTM's Capital Leases at $1.8 million in Q1 2022, $1.9 million in Q4 2021, and $2.1 million in Q3 2021.